You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 17, 2025

CLINICAL TRIALS PROFILE FOR VINCASAR PFS


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for VINCASAR PFS

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial TypeTrial IDTitleStatusSponsorPhaseStart DateSummary
OTC NCT03742258 ↗ Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma Active, not recruiting National Cancer Institute (NCI) Phase 1 2019-03-13 The purpose of this research study is to evaluate a new investigational drug, TAK-659, given in combination with standard chemotherapy, for the treatment of Diffuse Large B-cell Lymphoma (DLBCL). ?Investigational? means that TAK-659 has not been approved by the United States Food and Drug Administration (FDA) for use as a prescription or over-the-counter medication to treat a certain condition. The primary purpose of this study is to find the appropriate and safe dose of the study drug to be used in combination with standard chemotherapy for the treatment of your disease and to determine how well the drug works in treating the disease. Other objectives include measuring the amount of the study drug in the body at different times after taking the study drug. Participation in the study is expected to last for up to 3 years after receiving the last dose of the study drug. Patients will receive the study treatment for up to 18 weeks, as long as they are benefitting.
OTC NCT03742258 ↗ Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma Active, not recruiting Northwestern University Phase 1 2019-03-13 The purpose of this research study is to evaluate a new investigational drug, TAK-659, given in combination with standard chemotherapy, for the treatment of Diffuse Large B-cell Lymphoma (DLBCL). ?Investigational? means that TAK-659 has not been approved by the United States Food and Drug Administration (FDA) for use as a prescription or over-the-counter medication to treat a certain condition. The primary purpose of this study is to find the appropriate and safe dose of the study drug to be used in combination with standard chemotherapy for the treatment of your disease and to determine how well the drug works in treating the disease. Other objectives include measuring the amount of the study drug in the body at different times after taking the study drug. Participation in the study is expected to last for up to 3 years after receiving the last dose of the study drug. Patients will receive the study treatment for up to 18 weeks, as long as they are benefitting.
>Trial Type>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 2 of 2 entries

All Clinical Trials for VINCASAR PFS

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT00075725 ↗ Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia Completed National Cancer Institute (NCI) Phase 3 2003-12-29 This randomized phase III trial is studying dexamethasone to see how well it works compared to prednisone during induction therapy. This trial is also studying methotrexate and leucovorin calcium to see how well they work compared to methotrexate alone during maintenance therapy in treating patients with newly diagnosed acute lymphoblastic leukemia (ALL). Drugs used in chemotherapy, such as dexamethasone, prednisone, methotrexate, and leucovorin calcium, work in different ways to stop cancer cells from dividing so they stop growing or die. Giving more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating acute lymphoblastic leukemia.
NCT00075725 ↗ Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia Completed Children's Oncology Group Phase 3 2003-12-29 This randomized phase III trial is studying dexamethasone to see how well it works compared to prednisone during induction therapy. This trial is also studying methotrexate and leucovorin calcium to see how well they work compared to methotrexate alone during maintenance therapy in treating patients with newly diagnosed acute lymphoblastic leukemia (ALL). Drugs used in chemotherapy, such as dexamethasone, prednisone, methotrexate, and leucovorin calcium, work in different ways to stop cancer cells from dividing so they stop growing or die. Giving more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating acute lymphoblastic leukemia.
NCT00026208 ↗ Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma Completed Stanford University Phase 2 2001-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: This phase 2 trial is studying how well giving combination chemotherapy together with low-dose radiation therapy works in treating patients with stage I or stage IIA Hodgkin's lymphoma.
NCT00004010 ↗ Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease Completed National Cancer Institute (NCI) Phase 2 1999-10-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. Giving radiation therapy after chemotherapy may be an effective treatment for Hodgkin's disease. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and radiation therapy in treating children who have previously untreated stage II, stage III, or stage IV Hodgkin's disease.
NCT00004010 ↗ Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease Completed Children's Oncology Group Phase 2 1999-10-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. Giving radiation therapy after chemotherapy may be an effective treatment for Hodgkin's disease. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and radiation therapy in treating children who have previously untreated stage II, stage III, or stage IV Hodgkin's disease.
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 5 of 5 entries

Clinical Trial Conditions for VINCASAR PFS

Condition Name

201311110-20246810121416182022Acute Lymphoblastic LeukemiaUntreated Adult Acute Lymphoblastic LeukemiaB Acute Lymphoblastic LeukemiaUntreated Childhood Acute Lymphoblastic Leukemia[disabled in preview]
Condition Name for VINCASAR PFS
Intervention Trials
Acute Lymphoblastic Leukemia 20
Untreated Adult Acute Lymphoblastic Leukemia 13
B Acute Lymphoblastic Leukemia 11
Untreated Childhood Acute Lymphoblastic Leukemia 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

434240390051015202530354045LymphomaLeukemiaPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphoid[disabled in preview]
Condition MeSH for VINCASAR PFS
Intervention Trials
Lymphoma 43
Leukemia 42
Precursor Cell Lymphoblastic Leukemia-Lymphoma 40
Leukemia, Lymphoid 39
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for VINCASAR PFS

Trials by Country

+
Trials by Country for VINCASAR PFS
Location Trials
Canada 231
Australia 95
New Zealand 35
Puerto Rico 25
Switzerland 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State for VINCASAR PFS
Location Trials
Texas 62
Ohio 58
California 58
New York 56
Illinois 56
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for VINCASAR PFS

Clinical Trial Phase

34.1%37.4%24.2%05101520253035Phase 3Phase 2/Phase 3Phase 2[disabled in preview]
Clinical Trial Phase for VINCASAR PFS
Clinical Trial Phase Trials
Phase 3 31
Phase 2/Phase 3 4
Phase 2 34
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

41.4%33.3%17.2%8.0%05101520253035Active, not recruitingRecruitingCompleted[disabled in preview]
Clinical Trial Status for VINCASAR PFS
Clinical Trial Phase Trials
Active, not recruiting 36
Recruiting 29
Completed 15
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for VINCASAR PFS

Sponsor Name

trials0102030405060708090National Cancer Institute (NCI)Children's Oncology GroupM.D. Anderson Cancer Center[disabled in preview]
Sponsor Name for VINCASAR PFS
Sponsor Trials
National Cancer Institute (NCI) 85
Children's Oncology Group 25
M.D. Anderson Cancer Center 13
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

46.7%41.2%12.1%00102030405060708090NIHOtherIndustry[disabled in preview]
Sponsor Type for VINCASAR PFS
Sponsor Trials
NIH 85
Other 75
Industry 22
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

VINCASAR PFS: Clinical Trials, Market Analysis, and Projections

Introduction to VINCASAR PFS

VINCASAR PFS, also known as vincristine sulfate injection, is a chemotherapeutic agent derived from the periwinkle plant (Vinca rosea Linn). It is used in the treatment of various cancers, including acute leukemia, Hodgkin's disease, non-Hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor[2][4].

Mechanism of Action

The mechanism of action of vincristine sulfate involves the inhibition of microtubule formation in the mitotic spindle, leading to an arrest of dividing cells at the metaphase stage. This action is crucial in halting the proliferation of cancer cells[2].

Clinical Uses

VINCASAR PFS is FDA-approved for the treatment of acute leukemia and is often used in combination with other oncolytic agents for various other cancers. Its unique toxicity profile, particularly the lack of significant bone-marrow suppression at recommended doses, makes it a valuable component in polychemotherapy regimens[2][4].

Dosage and Administration

The dosage of VINCASAR PFS is carefully calculated due to its potential for neurotoxicity and other severe side effects. For pediatric patients, the usual dose is 1.5 to 2 mg/m², while for adults, it is 1.4 mg/m². The drug is administered intravenously at weekly intervals, and extreme care is necessary to avoid overdosage, which can be fatal[1][2].

Side Effects and Interactions

VINCASAR PFS is associated with several side effects, including neurotoxicity, paralytic ileus, genitourinary issues, cardiovascular effects, and hematologic changes such as anemia, leukopenia, and thrombocytopenia. It also interacts with other drugs, such as phenytoin and itraconazole, which can affect its metabolism and efficacy[1][2].

Current Clinical Trials Landscape

Overview of Clinical Trials

Clinical trials play a critical role in the development and approval of drugs like VINCASAR PFS. These trials are rigorously regulated by the FDA to ensure patient safety and data integrity. The U.S. clinical trials market, which includes trials for oncology drugs, is expected to grow significantly, driven by ongoing research efforts and the need for innovative healthcare solutions[3].

Phase I Trials

Phase I trials, which are the initial human testing phase for new drugs, are crucial for assessing the safety and pharmacokinetics of drugs like VINCASAR PFS. These trials are expected to exhibit the most rapid growth during the forecast period, reflecting their importance in transitioning from laboratory and animal testing to human subjects[3].

Oncology Segment

The oncology segment, which includes drugs like VINCASAR PFS, accounted for the maximum revenue share in the U.S. clinical trials market in 2023 and is anticipated to register the fastest CAGR over the forecast period. This growth is driven by the continuous need for effective cancer treatments and the significant investments in cancer research[3].

Market Analysis and Projections

Market Size and Growth

The U.S. clinical trials market, which encompasses trials for drugs like VINCASAR PFS, was valued at USD 25.81 billion in 2023 and is expected to grow to USD 41.57 billion by 2033. The oncology segment, in particular, is projected to continue its dominance and rapid growth[3].

Regional Dominance

North America, with its strong presence of leading pharmaceutical companies and advanced healthcare infrastructure, is expected to dominate the market for nephroblastoma treatment, which includes drugs like VINCASAR PFS. The Asia Pacific region is anticipated to be the fastest-growing region due to increasing investments in healthcare and research[5].

Distribution Channels

Hospital pharmacies are expected to contribute the highest market share for oncology drugs, including VINCASAR PFS, due to the complex treatment needs of patients that require specialized supervision and critical infrastructure[5].

Key Takeaways

  • Clinical Trials Growth: The U.S. clinical trials market, particularly the oncology segment, is poised for significant growth driven by ongoing research and the need for innovative treatments.
  • Oncology Dominance: The oncology segment, which includes drugs like VINCASAR PFS, will continue to dominate the market with the fastest CAGR.
  • Regional Trends: North America will remain a dominant region, while the Asia Pacific region will experience the fastest growth.
  • Distribution Channels: Hospital pharmacies will continue to play a crucial role in the distribution of oncology drugs.
  • Safety and Efficacy: Clinical trials will remain critical for ensuring the safety and efficacy of drugs like VINCASAR PFS.

FAQs

What is VINCASAR PFS used for?

VINCASAR PFS is used in the treatment of acute leukemia and in combination with other agents for the treatment of Hodgkin's disease, non-Hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor[2][4].

How is VINCASAR PFS administered?

VINCASAR PFS is administered intravenously at weekly intervals. The dosage is carefully calculated to avoid neurotoxicity and other severe side effects[1][2].

What are the common side effects of VINCASAR PFS?

Common side effects include neurotoxicity, paralytic ileus, genitourinary issues, cardiovascular effects, and hematologic changes such as anemia, leukopenia, and thrombocytopenia[1][2].

How does VINCASAR PFS interact with other drugs?

VINCASAR PFS interacts with drugs like phenytoin and itraconazole, which can affect its metabolism and efficacy. Caution is advised when using these drugs concurrently[1][2].

What is the projected growth of the U.S. clinical trials market?

The U.S. clinical trials market is expected to grow from USD 27.07 billion in 2024 to USD 41.57 billion by 2033, with the oncology segment experiencing the fastest CAGR[3].

Sources

  1. RxList: Vincasar PFS (Vincristine Sulfate Injection) - RxList
  2. Drugs.com: Vincasar PFS: Package Insert / Prescribing Information - Drugs.com
  3. Biospace: U.S. Clinical Trials Market Size Industry Analysis Report, 2033
  4. Tahoe Forest Health System: Vincasar® PFS | Tahoe Forest Health System
  5. Coherent Market Insights: Nephroblastoma Treatment Market - Trends, Size, Share & Forecast

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.